
# **Results Report 2024**

## At a glance





## State of the fight and key results 2023

The Global Fund partnership made significant progress in the fight against HIV, tuberculosis (TB) and malaria in 2023. In countries where the Global Fund invests, the response to HIV, TB and malaria fully recovered from the disruptions caused by COVID-19 thanks to the efforts by governments, communities, the private sector, civil society and our technical partners. In 2023, we invested the highest amount ever in a single calendar year to strengthen health and community systems. Since 2002, our partnership has cut the combined death rate from AIDS, TB and malaria by 61%. As of the end of 2023, the Global Fund partnership has saved 65 million lives.



The Global Fund provides 28% of all international financing for HIV programs. In countries where we invest, AIDS-related deaths reduced by 73% between 2002 and 2023. We supported increased access to effective prevention options, including oral PrEP and the dapivirine vaginal ring, and put more people on HIV treatment. In 2023, we secured a 25% price reduction for the preferred first-line HIV treatment, enabling governments to invest in other critical areas. We continued to tackle human rights and gender-related barriers to HIV services.

## 25 M

people on antiretroviral therapy for HIV.

## 53.8 M

**HIV tests taken** (13.1 M by priority and key populations).

#### 17.9 M

**people reached with HIV prevention services** (8 M people from key populations).

#### 695 K

mothers living with HIV received medicine to keep them alive and prevent transmitting HIV to their babies.

#### 925 K

voluntary medical male circumcisions performed for HIV prevention.

#### **322 K**

people initiated oral antiretroviral pre-exposure prophylaxis.



#### **Tuberculosis**

The Global Fund provides 76% of all international financing for TB programs. In countries where we invest, TB deaths (excluding people living with HIV) reduced by 36% between 2002 and 2022. In 2023, we supported countries to deliver equitable and cost-effective TB interventions, including finding and treating "missing" people with TB, supporting the rollout of better treatment regimens and increasing the availability of screening and diagnostics. We achieved price reductions for key TB commodities, including a 55% price reduction for bedaquiline, the main treatment for drug-resistant TB.

#### 7.1 M

people treated for TB.

#### 121 K

people on treatment for drug-resistant TB.

#### 353 K

HIV-positive TB patients on antiretroviral therapy.

#### 1.7 M

people living with HIV on antiretroviral therapy initiated TB preventive therapy.

#### 2 M

people exposed to TB received preventive therapy.



#### Malaria

The Global Fund provides 62% of all international financing for malaria programs. In countries where we invest, malaria deaths have gone down by 28% between 2002 and 2022. In 2023, the Global Fund expanded access to tools to prevent and treat malaria, including mosquito nets, seasonal malaria chemoprevention for children, preventive treatment of malaria during pregnancy, and antimalarial medicines. We secured new dual active ingredient insecticide-treated nets, which are more effective against insecticide-resistant mosquitoes than conventional ones, at a comparable price.

## **227 M**

mosquito nets distributed to protect families from malaria.

#### 335 M

suspected cases of malaria tested.

#### 171 M

cases of malaria treated.

#### 44.6 M

children received seasonal malaria chemoprevention.

#### 15.5 M

pregnant women received preventive treatment for malaria.



## Strengthening health and community systems

The Global Fund is the world's largest multilateral grants provider for health and community systems in low- and middle-income countries. In 2023, we invested US\$1.8 billion, accelerating our efforts by reinvesting COVID-19 Response Mechanism funding. Between 2024-2026, we are investing an estimated US\$6 billion to support countries to deliver better health outcomes across all diseases, build pandemic preparedness and work towards achieving universal health coverage.

Besides our direct investments in health and community systems, our funding in the fight against HIV, TB and malaria has freed up resources and capacities, making countries and communities better able to respond to other diseases and health concerns. Our investments in HIV up to the end of 2023 have freed up 1.66 billion HIV-related hospitalization days and averted 1.36 billion outpatient visits, which generated US\$85 billion in cost savings.

#### **Number of HIV-related hospitalization days avoided**

In countries where the Global Fund invests, 2002-2023



3.8M

Middle East and North Africa (0.2%)

World Bank regions. This chart includes countries that received an allocation from the Global Fund since our inception up until 2023. Figures in millions (M), billions (B).

## **Colliding crises**

In 2023, the world faced multiple crises including climate change, conflict, antigender and anti-rights movements and attacks on civil society, causing deepening inequities within and between countries. These challenges put the poorest and the most marginalized people at greater risk of infectious diseases.

The Global Fund is uniquely positioned to respond to these crises. In addition to strengthening countries' health and community systems, we provide emergency funds and partner with humanitarian organizations to support populations affected by crises. In 2023, we expanded our Breaking Down Barriers initiative to tackle human rights and gender-related barriers to accessing health services.

We adapted our interventions to provide agile support, ensuring the continuity of HIV, TB and malaria programs in challenging contexts. In 2023, the Global Fund announced new strategic partnerships with the World Bank and the Green Climate Fund to accelerate investments in the nexus between climate and health.



© UNICEF/UNI424978/Sokhin



The Global Fund is a worldwide partnership to defeat HIV, TB and malaria and ensure a healthier, safer, more equitable future for all. We raise and invest more than US\$5 billion a year to fight the deadliest infectious diseases, challenge the injustice that fuels them, and strengthen health systems and pandemic preparedness in more than 100 of the hardest hit countries. We unite world leaders, communities, civil society, health workers and the private sector to find solutions that have the most impact, and we take them to scale worldwide. Since 2002, the Global Fund partnership has saved 65 million lives.